US · Healthcare · Biotechnology
EPS came in at -0.53 against a street estimate of -0.43 — a miss of 23.3%.
Analysts rate Immatics NV a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $16.97.
| Fund | Stake |
|---|---|
| T. Rowe Price Investment Management,Inc. | 14.69% |
| RTW INVESTMENTS, LLC | 8.50% |
| Suvretta Capital Management, LLC | 7.35% |
| Perceptive Advisors LLC | 6.82% |
| Baker Bros Advisors LP | 6.25% |
| Jefferies Financial Group Inc | 4.27% |
| Vestal Point Capital LP | 4.06% |
| Sofinnova Ventures | 2.41% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Immatics is developing three clinical PRAME-targeting candidates across two treatment approaches: cell therapies and bispecific T- | 2026-10-26 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • IMA203CD8 is an investigational, one-time TCR T-cell therapy targeting the intracellular cancer antigen PRAME in HLA-A*02:01-posit | 2026-10-23 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Immatics N.V. plans to issue and sell 12,945,916 ordinary shares with a nominal value of €0.01 per share. • It also plans to issu | 2026-08-26 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 revenue from collaboration agreements was €9,144 thousand, up from €4,737 thousand in Q2 2025. • First-half 2026 collabor | 2026-08-18 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • Immatics N.V. held its Annual General Meeting of Shareholders on June 18, 2026. • Shareholders approved every item on the meetin | 2026-06-18 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • Immatics N.V. adopted the 2026 Stock Option and Incentive Plan to provide equity-based incentives to officers, employees, non-empl | 2026-06-02 |
| Quarterly results (6-K) · Q1 2026 HEADLINE NUMBERS • Immatics reported Q1 2026 revenue of €7,612 thousand, down from €18,582 thousand in Q1 2025. • Research and development expenses | 2026-05-12 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Fiscal year ended December 31, 2025; financial statements are prepared under IFRS in euros. • Immatics had 134,071,432 ordinary s | 2026-03-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immatics NV — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.